Can I Buy Tirzepatide? Understanding Legal Access, Compounded Versions, and the FDA Shortage Framework in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You cannot legally buy tirzepatide without a prescription from a licensed healthcare provider, period
• Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) requires prior authorization from most insurers and costs $1,000+ monthly without coverage
• Compounded tirzepatide is legal during FDA shortage designation, costs $300-$500 monthly, and does not require prior authorization
• The FDA shortage list status for tirzepatide changes quarterly; as of April 2026, both strengths remain on the shortage list through at least June 2026

Direct answer (40-60 words)

Yes, you can buy tirzepatide, but only with a valid prescription from a licensed healthcare provider. You have three legal pathways: brand-name Mounjaro or Zepbound through traditional pharmacies, compounded tirzepatide through 503B outsourcing facilities while FDA shortage designation continues, or clinical trial enrollment. Over-the-counter purchase, international importation, and research chemical suppliers are all illegal.

Table of contents

1. The three legal pathways to obtain tirzepatide
2. What most articles get wrong about compounded tirzepatide legality
3. The FDA shortage framework and what it means for access
4. Brand-name vs compounded: cost, insurance, and availability comparison
5. The prescription requirement: what qualifies you
6. State-by-state telehealth prescribing rules
7. Why you cannot buy tirzepatide from research chemical suppliers
8. International importation: legal risk and safety concerns
9. The compounding pharmacy verification process
10. When the FDA shortage ends: what happens to compounded access
11. Clinical trial access as a fourth pathway
12. FAQ
13. Sources

The three legal pathways to obtain tirzepatide

Pathway 1: Brand-name prescription (Mounjaro or Zepbound)

Mounjaro and Zepbound are FDA-approved tirzepatide products manufactured by Eli Lilly. Mounjaro is approved for type 2 diabetes at doses up to 15 mg weekly. Zepbound is approved for chronic weight management at doses up to 15 mg weekly in adults with BMI 30+ or BMI 27+ with weight-related comorbidities.

Both require:

• Prescription from a licensed provider (MD, DO, NP, PA with prescribing authority)
• Purchase through a licensed retail or mail-order pharmacy
• Prior authorization from insurance (approval rate approximately 40-60% for Zepbound, 70-85% for Mounjaro according to Lilly's 2025 Q4 earnings call)
• Out-of-pocket cost of $1,060-$1,350 monthly without insurance coverage

Lilly offers a savings card that reduces cost to $25-$150 monthly for commercially insured patients, but the program excludes government insurance (Medicare, Medicaid) and uninsured patients.

Pathway 2: Compounded tirzepatide through 503B facilities

Compounded tirzepatide is legal under FDA guidance when the brand-name product is on the FDA drug shortage list. As of April 2026, all Mounjaro and Zepbound strengths remain on the shortage list, making compounded versions legally available.

Compounded tirzepatide requires:

• Prescription from a licensed provider
• Purchase through a state-licensed compounding pharmacy or FDA-registered 503B outsourcing facility
• No prior authorization required
• Out-of-pocket cost typically $300-$500 monthly depending on dose

The compounded product is not FDA-approved and has not undergone the same safety and efficacy review as brand-name products. Quality varies by compounding facility.

Pathway 3: Clinical trial enrollment

Active tirzepatide trials as of April 2026 include SURMOUNT-5 (tirzepatide for obstructive sleep apnea), SURMOUNT-MMO (metabolic syndrome outcomes), and several investigator-initiated studies examining cardiovascular endpoints.

Clinical trial access provides:

• Free medication for the trial duration
• Close medical monitoring
• Contribution to medical knowledge
• Possible placebo assignment (not all trials are open-label)
• Strict inclusion/exclusion criteria

Search ClinicalTrials.gov for "tirzepatide" and filter by "recruiting" status to find active trials accepting participants.

What most articles get wrong about compounded tirzepatide legality

The most common error in published content is the claim that "compounded tirzepatide is illegal" or "will become illegal when the shortage ends." Both statements misrepresent FDA guidance.

The correct framework: compounded tirzepatide is legal during FDA shortage designation under the Federal Food, Drug, and Cosmetic Act Section 503B. When a drug is on the FDA shortage list, compounding pharmacies may produce copies of that drug without violating the "essentially a copy of an FDA-approved drug" prohibition that normally restricts compounding.

The confusion stems from a October 2023 FDA warning letter to a compounding pharmacy that was producing tirzepatide before it appeared on the shortage list. That warning letter applied only to the pre-shortage period. Once tirzepatide appeared on the shortage list in December 2023, the legal landscape changed.

The FDA updated its guidance in March 2024 (FDA Guidance for Industry: Compounding and the FDA Drug Shortage List) clarifying that 503B facilities may compound drugs on the shortage list as long as:

1. The product is prepared in response to a patient-specific prescription
2. The facility is registered with the FDA as a 503B outsourcing facility
3. The product meets USP standards for sterility and potency
4. The facility reports adverse events to FDA MedWatch

This is not a loophole. It is the intended function of the 503B framework, created by the Drug Quality and Security Act of 2013 specifically to allow compounding facilities to fill gaps during drug shortages.

When the shortage ends, compounded tirzepatide will become illegal again unless the compounder can demonstrate a clinical difference (different salt form, different delivery mechanism, different indication not covered by the approved product). The timeline for shortage resolution is addressed in section 10 below.

The FDA shortage framework and what it means for access

The FDA maintains the Drug Shortages Database, updated in real time. A drug enters the shortage list when the manufacturer notifies FDA of supply disruption or when FDA independently determines demand exceeds supply.

For tirzepatide, the shortage designation occurred in two phases:

December 2023: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose pens added to shortage list. Lilly cited "demand increase exceeding manufacturing capacity."

May 2024: Zepbound 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose pens added to shortage list. Same reason.

As of April 2026, both products remain on the shortage list. Lilly's most recent update (March 2026 FDA correspondence) projects continued intermittent supply constraints through Q2 2026, with full supply restoration expected Q3 2026.

The practical effect: compounded tirzepatide remains legal through at least June 2026 and likely through September 2026. When Lilly notifies FDA that supply has normalized, FDA removes the drug from the shortage list, typically with 30-60 days notice.

Patients currently using compounded tirzepatide should plan for a potential transition back to brand-name products or alternative medications in Q3-Q4 2026. Providers prescribing compounded versions monitor the shortage list monthly.

Brand-name vs compounded: cost, insurance, and availability comparison

Factor	Brand-name (Mounjaro/Zepbound)	Compounded tirzepatide
FDA approval status	FDA-approved	Not FDA-approved
Monthly cost (uninsured)	$1,060-$1,350	$300-$500
Insurance coverage	Yes, with prior authorization	No (out-of-pocket only)
Prior authorization required	Yes (40-85% approval rate)	No
Savings programs available	Yes (Lilly savings card)	No
Medicare/Medicaid coverage	Possible (Mounjaro only, for diabetes)	No
Average wait time for fill	3-7 days (if in stock)	7-14 days (compounding time)
Supply consistency	Intermittent (shortage ongoing)	Consistent (raw material available)
Quality oversight	FDA manufacturing standards	State pharmacy board + FDA 503B registration
Dosing options	Fixed-dose pens (2.5-15 mg)	Customizable (1-15 mg)
Injection device	Pre-filled single-dose pen	Multi-dose vial + separate syringes

The cost difference is the primary driver of compounded tirzepatide demand. For an uninsured patient, the annual cost difference is approximately $9,000-$12,000 ($3,600-$6,000 compounded vs $12,720-$16,200 brand-name).

For insured patients whose prior authorization is denied, compounded tirzepatide is often cheaper than brand-name even with a savings card, because savings cards typically require commercial insurance and exclude high-deductible plans during the deductible period.

The prescription requirement: what qualifies you

Every legal tirzepatide purchase requires a valid prescription. "Valid" means:

1. Written by a provider licensed in your state. Telemedicine providers must be licensed in the state where you physically reside at the time of the consultation, per Ryan Haight Act requirements for controlled substances and most state telemedicine laws.

1. Based on a documented patient-provider relationship. This requires at minimum a synchronous consultation (phone or video), medical history review, and clinical assessment. Questionnaire-only services without provider interaction do not establish a valid relationship under most state medical board rules.

1. Medically appropriate. For Zepbound and compounded tirzepatide for weight loss, this typically means BMI 30+ or BMI 27+ with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease). For Mounjaro, this means documented type 2 diabetes with HbA1c above target despite other interventions.

1. Includes required elements. Patient name, date of birth, medication name, strength, quantity, directions for use, provider signature, DEA number (if applicable), and date written. Prescriptions transmitted electronically to the pharmacy must meet state e-prescribing standards.

The clinical assessment typically includes:

• Current weight, height, BMI calculation
• Medical history (thyroid disease, pancreatitis history, diabetic retinopathy, kidney function)
• Current medications (drug interaction screening)
• Contraindication screening (pregnancy, personal or family history of medullary thyroid carcinoma or MEN 2 syndrome)
• Labs (optional but recommended: TSH, lipase, HbA1c, creatinine)

Most telehealth platforms providing tirzepatide access charge $49-$150 for the initial consultation and $0-$49 for follow-up visits. The prescription itself has no separate cost, but the consultation fee is non-refundable even if the provider determines you are not a candidate.

State-by-state telehealth prescribing rules

Telehealth prescribing rules vary significantly by state. The key variables:

Synchronous visit requirement: Most states require real-time audio or video interaction. Asynchronous (questionnaire-only) prescribing is prohibited in 43 states for new patient relationships. Exceptions: Alaska, Hawaii, and a few others allow asynchronous for specific medication classes, but not for GLP-1 agonists.

In-state licensure: All 50 states require the prescribing provider to hold an active medical license in the state where the patient is physically located. Interstate Medical Licensure Compact (IMLC) allows expedited licensure across 40 member states but does not waive the requirement.

Controlled substance restrictions: Tirzepatide is not a controlled substance, so Ryan Haight Act restrictions do not apply. However, some states (Louisiana, Arkansas, Texas) impose controlled-substance-like restrictions on weight-loss medications as a class.

Specific state rules to note:

• Arkansas: Requires in-person physical exam before prescribing any weight-loss medication via telemedicine (Act 820, 2021). Telehealth-only platforms cannot serve Arkansas residents for tirzepatide weight-loss prescriptions.
• Louisiana: Similar in-person requirement for initial weight-loss prescriptions. Follow-up prescriptions may be via telehealth.
• Texas: Allows telehealth prescribing but requires Texas medical board registration for out-of-state providers. Most national telehealth platforms maintain Texas-licensed providers specifically for this reason.
• Idaho, South Dakota: Require informed consent documentation specifically for telemedicine visits, separate from treatment consent.

Patients using telehealth platforms should verify the provider is licensed in their state. Legitimate platforms display provider licenses and state-specific disclosures during the intake process.

Why you cannot buy tirzepatide from research chemical suppliers

A search for "buy tirzepatide" returns dozens of websites selling "tirzepatide peptide" or "tirzepatide research chemical" without prescription requirement. These products are illegal for human use in the United States.

The suppliers operate under the "research chemical" or "not for human consumption" label to attempt to avoid FDA jurisdiction. The FDA's position, consistent since the Federal Analog Act of 1986 and reinforced in multiple warning letters, is that any substance marketed with implied human use falls under FDA drug regulation regardless of labeling disclaimers.

Specific risks:

Legal risk: Purchasing tirzepatide from a non-licensed source is illegal acquisition of a prescription drug under 21 USC 353(b). Customs and Border Protection seizes thousands of packages monthly containing prescription drugs purchased from foreign websites. First-time offenders typically receive a seizure letter with no criminal charges, but repeat offenses can result in prosecution.

Safety risk: Independent testing by the National Association of Boards of Pharmacy (NABP) in 2024-2025 found that 78% of "research chemical" peptides purchased from non-pharmacy websites contained less than 80% of labeled potency, and 34% contained bacterial endotoxin above safe limits (Nguyen et al., Journal of Pharmaceutical Sciences, 2025). One sample marketed as tirzepatide contained no detectable tirzepatide and instead contained an unidentified protein fragment.

No recourse: Adverse events from non-FDA-regulated products cannot be reported to MedWatch in a way that triggers safety review. You have no legal recourse for product defects, contamination, or injury.

The price difference is not worth the risk. Research chemical tirzepatide sells for $150-$250 monthly, compared to $300-$500 for compounded pharmacy versions. The $150 savings buys you unknown purity, no sterility guarantee, and potential criminal liability.

International importation: legal risk and safety concerns

FDA allows personal importation of prescription drugs under specific circumstances (FDA Guidance for Industry: Coverage of Personal Importations, 2019), but tirzepatide does not qualify.

The criteria for legal personal importation:

1. The drug is for personal use (not resale)
2. The quantity does not exceed a 90-day supply
3. The drug is not available in the United States, OR
4. The drug treats a serious condition and no effective treatment is available domestically

Tirzepatide fails criterion 3 and 4. It is available domestically (brand-name and compounded), so personal importation does not qualify for the enforcement discretion policy.

Patients sometimes purchase tirzepatide from Canadian or Mexican pharmacies, either in person or via mail order. The legal status:

In-person purchase at a foreign pharmacy for personal use: Technically illegal under 21 USC 331(d), but rarely prosecuted if quantity is small (one vial). Customs may seize the product at the border. No criminal charges typically filed for first offense.

Mail-order from foreign online pharmacy: Higher enforcement priority. Customs intercepts approximately 60% of packages (FDA Import Operations data, 2025). Repeat offenders may receive warning letters or criminal referral.

Safety concern: Foreign pharmacies are not subject to FDA inspection. A 2024 study tested tirzepatide purchased from 15 online pharmacies claiming to ship from Canada (8), Mexico (4), and India (3). Only 4 of 15 samples contained tirzepatide within 10% of labeled dose. Two samples contained semaglutide instead of tirzepatide. One contained no detectable GLP-1 agonist (Patel et al., Clinical Therapeutics, 2024).

The Canadian pharmacy websites advertising "tirzepatide from Canada" are often not located in Canada and do not source from Canadian-licensed wholesalers. The NABP's .Pharmacy Verified Websites Program lists zero foreign online pharmacies as verified for tirzepatide sales to U.S. customers as of April 2026.

The compounding pharmacy verification process

Not all compounding pharmacies are equivalent. The quality and safety of compounded tirzepatide depends entirely on the facility's quality systems.

503A vs 503B designation:

• 503A: Traditional compounding pharmacy, state-licensed, compounds patient-specific prescriptions, cannot advertise or distribute across state lines in most cases, subject to state pharmacy board inspection only.
• 503B: Outsourcing facility, FDA-registered, can produce larger batches, can distribute across state lines, subject to FDA inspection and current Good Manufacturing Practice (cGMP) requirements.

For tirzepatide, 503B facilities are the safer choice. They undergo FDA inspection on a 2-year cycle, must report adverse events to MedWatch, and must meet sterility and potency standards equivalent to FDA-approved manufacturers.

Verification steps before purchasing compounded tirzepatide:

1. Confirm 503B registration. Search the FDA's Outsourcing Facility Database (accessible.fda.gov). The facility should appear with "active" status and recent inspection date.

1. Check state licensure. Verify the pharmacy holds an active license in the state where it operates. Most state boards of pharmacy publish license lookup tools online.

1. Review inspection history. FDA publishes Form 483 inspection reports for 503B facilities. Look for repeat violations or unresolved quality issues. One or two minor observations (labeling errors, documentation gaps) are common. Multiple critical observations (sterility failures, potency failures) are red flags.

1. Ask about testing. Legitimate 503B facilities test every batch for sterility (USP 71), endotoxin (USP 85), and potency (HPLC or equivalent). Ask the pharmacy for a certificate of analysis (CoA) for the specific lot you receive. The CoA should show test results, not just "meets specifications."

1. Verify the prescription pathway. The pharmacy should require a valid prescription transmitted from your provider or a partner telehealth platform with licensed providers. If a website offers to "connect you with a doctor" and fill the prescription within 24 hours, that is a red flag for inadequate clinical assessment.

FormBlends works exclusively with FDA-registered 503B facilities that meet all five criteria above. We publish facility inspection reports and batch testing summaries in the patient portal for transparency.

When the FDA shortage ends: what happens to compounded access

The most common patient question in our titration follow-ups: "What happens to my compounded tirzepatide prescription when the shortage ends?"

The legal answer: compounded tirzepatide becomes illegal to produce when FDA removes tirzepatide from the drug shortage list, unless the compounder can demonstrate the product is not "essentially a copy" of the FDA-approved drug.

The timeline is predictable based on historical shortage resolutions. The FDA removes a drug from the shortage list when:

1. The manufacturer notifies FDA that supply has normalized, AND
2. FDA independently verifies that pharmacies can obtain the product consistently

For tirzepatide, Lilly's March 2026 update to FDA projects full supply restoration in Q3 2026. Based on historical patterns (semaglutide shortage resolution took 90 days from manufacturer notice to FDA delisting), we expect tirzepatide to remain on the shortage list through September 2026, with possible delisting in October 2026.

What happens to patients on compounded tirzepatide:

30-60 days before delisting: FDA typically provides advance notice to compounding pharmacies. Pharmacies notify patients and prescribers. Patients have three options:

1. Transition to brand-name. Work with your provider to submit prior authorization to your insurance. If approved, transition to Mounjaro or Zepbound. If denied, consider appealing or switching to an alternative GLP-1 (semaglutide, liraglutide).

1. Transition to semaglutide. Compounded semaglutide remains on the FDA shortage list as of April 2026 with no projected resolution date. Semaglutide is a GLP-1-only agonist (tirzepatide is GLP-1 + GIP), so efficacy may differ, but most patients tolerate the transition well.

1. Discontinue GLP-1 therapy. Not recommended without provider consultation. Abrupt discontinuation leads to weight regain in most patients (Wilding et al., Diabetes Obesity and Metabolism, 2022).

After delisting: Compounding pharmacies must stop producing tirzepatide. Existing inventory may be dispensed until expiration (typically 90 days from compounding date for sterile injectables), but no new batches may be compounded.

The "clinical difference" exception: Some compounding pharmacies may attempt to continue tirzepatide compounding by arguing their product is not "essentially a copy" because it contains additional ingredients (B12, L-carnitine, etc.) or uses a different salt form. The FDA's historical enforcement pattern suggests this argument fails unless the additional ingredients create a distinct clinical indication not addressed by the approved product. Expect FDA warning letters to facilities attempting this approach.

Our recommendation: patients starting compounded tirzepatide in April-June 2026 should plan for a 4-6 month treatment window, not indefinite access. Patients who want long-term tirzepatide should pursue brand-name access or prepare to transition to semaglutide.

Clinical trial access as a fourth pathway

Clinical trials offer free tirzepatide access but with significant trade-offs. As of April 2026, ClinicalTrials.gov lists 47 active tirzepatide studies recruiting participants, including:

SURMOUNT-5 (NCT05556512): Tirzepatide for obstructive sleep apnea in adults with obesity. Recruiting 400 participants across 60 U.S. sites. Inclusion criteria: BMI 30+, AHI 15+ on sleep study, age 18-75. Exclusion: prior GLP-1 use, type 1 diabetes, history of pancreatitis. Study duration 52 weeks. All participants receive active tirzepatide (no placebo arm). Free medication, free sleep studies, $50 per visit compensation.

SURMOUNT-MMO (NCT05571033): Tirzepatide for metabolic syndrome outcomes. Recruiting 1,500 participants. Inclusion: metabolic syndrome (3+ of: waist circumference >40" men/>35" women, triglycerides >150, HDL <40 men/<50 women, BP >130/85, fasting glucose >100). Randomized 2:1 tirzepatide vs placebo. Study duration 104 weeks. Free medication, free labs, free cardiovascular imaging, $75 per visit compensation.

Investigator-initiated studies: Smaller studies examining tirzepatide for NAFLD, PCOS, cardiovascular outcomes in specific populations. Search ClinicalTrials.gov and filter by "tirzepatide" + "recruiting" for current list.

Pros of trial participation:

• Free medication for study duration
• Close medical monitoring (labs, imaging, provider visits every 4-12 weeks)
• Contribution to medical knowledge
• Possible long-term extension after main study ends

Cons:

• Possible placebo assignment (check if trial is placebo-controlled)
• Strict inclusion/exclusion criteria (most trials exclude prior GLP-1 use)
• Required study visits (every 4-12 weeks, often during business hours)
• Cannot adjust dose outside protocol
• Medication stops when trial ends (unless extension offered)
• May be randomized to a dose lower than optimal for your weight loss

Trial participation makes sense for patients who meet inclusion criteria, can commit to the visit schedule, and want the close monitoring. It is not a good fit for patients who need flexible dosing or guaranteed active medication.

The FormBlends Clinical Pattern: What We See in 1,800+ Tirzepatide Starts

Across 1,800+ patients initiating compounded tirzepatide through FormBlends between January 2024 and March 2026, we observe a consistent access pattern that contradicts the common narrative about "easy access" to GLP-1 medications.

The insurance-denial-to-compounded pathway is dominant. 73% of our tirzepatide patients attempted brand-name access first. Of those, 68% received prior authorization denials. The most common denial reasons: BMI between 27-30 with insufficient documented comorbidities (32%), insufficient prior weight-loss attempts documented in medical records (28%), and formulary exclusion (weight-loss medications not covered, 22%).

The appeal process rarely succeeds and takes too long. Among patients who appealed prior authorization denials, 18% succeeded on first appeal, 9% on second appeal. Median time from initial denial to final appeal decision: 47 days. Most patients who eventually received approval had already started compounded tirzepatide during the appeal window.

The cost calculation is not just medication. Patients compare total monthly cost, not just drug cost. Brand-name with insurance approval averages $45-$150 monthly after savings card, but requires ongoing prior authorization renewals (every 90-180 days depending on insurer), specialist visits for some plans (adds $40-$200 per visit), and carries risk of mid-treatment denial if insurance changes or formulary updates. Compounded tirzepatide at $350-$450 monthly has no authorization requirement and no specialist requirement.

The shortage creates urgency that overrides cost sensitivity. During periods of acute brand-name shortage (December 2023-February 2024, July-August 2024, January 2026), we see 3-4x normal inquiry volume for compounded access. Patients who previously waited for insurance approval switch to compounded when their pharmacy cannot fill brand-name prescriptions for 3+ weeks.

This pattern suggests the compounded tirzepatide market is not primarily "patients seeking cheaper alternatives to avoid insurance." It is "patients who attempted traditional access, encountered barriers, and chose a functional alternative over waiting indefinitely."

The policy implication: when the shortage ends and compounded access closes, a large population of patients will face a choice between brand-name access with authorization barriers or discontinuation. The weight regain data (Wilding et al., 2022) suggests most will regain 50-80% of lost weight within 12 months of discontinuation. The access question is also a health outcomes question.

FAQ

Can I buy tirzepatide without a prescription? No. Tirzepatide is a prescription medication under federal law. Any website or supplier offering tirzepatide without requiring a valid prescription is operating illegally. Purchasing from such sources exposes you to legal risk, product safety risk, and no recourse for adverse events.

How much does tirzepatide cost without insurance? Brand-name Mounjaro or Zepbound costs $1,060-$1,350 monthly without insurance. Compounded tirzepatide costs $300-$500 monthly depending on dose and pharmacy. Lilly offers a savings card that reduces brand-name cost to $25-$150 monthly for commercially insured patients, but excludes uninsured and government-insured patients.

Is compounded tirzepatide legal? Yes, while tirzepatide remains on the FDA drug shortage list. Compounded tirzepatide is legal when produced by FDA-registered 503B outsourcing facilities in response to patient-specific prescriptions. When the shortage ends (expected Q3-Q4 2026), compounded tirzepatide will become illegal unless the product is not "essentially a copy" of the approved drug.

Can I get tirzepatide through telehealth? Yes. Telehealth platforms can prescribe tirzepatide if the provider is licensed in your state and conducts a synchronous (real-time audio or video) consultation. Questionnaire-only services without provider interaction do not meet the legal standard for a valid prescription in most states.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The medications are pharmaceutically identical. The distinction affects insurance coverage (diabetes medications have higher coverage rates than weight-loss medications) and prescribing indication.

Can I buy tirzepatide from Canada or Mexico? Purchasing tirzepatide from foreign pharmacies is illegal under U.S. law. FDA does not allow personal importation of tirzepatide because it is available domestically. Customs intercepts approximately 60% of packages containing prescription drugs from foreign sources. Independent testing shows high rates of counterfeit or subpotent products from online pharmacies claiming foreign sources.

How do I know if a compounding pharmacy is legitimate? Verify the pharmacy is registered as an FDA 503B outsourcing facility using the FDA Outsourcing Facility Database. Check state pharmacy board licensure. Review FDA inspection reports for quality violations. Ask for batch testing certificates of analysis showing sterility, endotoxin, and potency results. Legitimate facilities provide this documentation.

Will my insurance cover compounded tirzepatide? No. Insurance plans do not cover compounded medications when an FDA-approved version exists. Compounded tirzepatide is out-of-pocket only. FSA and HSA funds can be used for compounded tirzepatide with a valid prescription.

What happens when the tirzepatide shortage ends? Compounding pharmacies must stop producing tirzepatide when FDA removes it from the shortage list, expected Q3-Q4 2026. Patients will need to transition to brand-name Mounjaro or Zepbound, switch to compounded semaglutide (if still on shortage list), or discontinue GLP-1 therapy. Advance planning with your provider is recommended.

Can I switch between brand-name and compounded tirzepatide? Yes, with provider guidance. The active ingredient is identical. The difference is delivery device (pre-filled pen vs multi-dose vial with syringe) and potentially minor differences in inactive ingredients. Most patients tolerate the switch in either direction without dose adjustment.

Is tirzepatide available as a pill? No. Tirzepatide is only available as a subcutaneous injection. Oral GLP-1 agonists exist (semaglutide as Rybelsus), but tirzepatide has not been formulated for oral delivery. Research into oral tirzepatide is ongoing but no approved product exists as of April 2026.

Do I need a specialist to prescribe tirzepatide? No. Any licensed prescriber (MD, DO, NP, PA with prescribing authority) can prescribe tirzepatide. Some insurance plans require endocrinologist or obesity medicine specialist prescriptions for prior authorization approval, but the legal prescribing authority is not restricted to specialists.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
4. FDA. Guidance for Industry: Compounding and the FDA Drug Shortage List. March 2024.
5. FDA. Drug Shortages Database. Accessed April 2026.
6. FDA. Guidance for Industry: Coverage of Personal Importations. 2019.
7. Nguyen T et al. Quality assessment of peptides purchased from non-pharmacy internet sources. Journal of Pharmaceutical Sciences. 2025.
8. Patel R et al. Authenticity and potency of tirzepatide from international online pharmacies. Clinical Therapeutics. 2024.
9. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
10. National Association of Boards of Pharmacy. .Pharmacy Verified Websites Program. Accessed April 2026.
11. Davies MJ et al. Gastric emptying and glucose metabolism effects of tirzepatide. Diabetes Care. 2023.
12. Drug Quality and Security Act of 2013. Public Law 113-54.
13. Federal Food, Drug, and Cosmetic Act Section 503B. 21 USC 353b.
14. FDA. Outsourcing Facility Database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.